Zobrazeno 1 - 5
of 5
pro vyhledávání: '"329"'
Autor:
Kathryn Humphrey, Alexandra Bazeos, Francine Swann, Nelson Kinnersley, Othman Al-Sawaf, Noelle Crompton, Craig Gower, Günter Fingerle-Rowson, Peter Trask, Mark Dixon, Valentin Goede
Publikováno v:
Blood. 128:4352-4352
BACKGROUND The evaluation of response to therapy in CLL is widely assessed according to the iwCLL guidelines which define progressive disease (PD) as advancing lymphocytosis, lymphadenopathy, organomegaly, cytopenias or histological transformation (H
Autor:
Wilson I. Gonsalves, Ronald S. Go, Nidhi Tandon, John A. Lust, Amie Fonder, Surbhi Sidana, Angela Dispenzieri, Nelson Leung, Steven R. Zeldenrust, Suzanne R. Hayman, Miriam Hobbs, Shaji Kumar, Martha Q. Lacy, Robert A. Kyle, Stephen J. Russell, Yi L. Hwa, Francis K. Buadi, S. Vincent Rajkumar, David Dingli, Morie A. Gertz, Prashant Kapoor
Publikováno v:
Blood. 128:4627-4627
Introduction High dose chemotherapy and autologous stem cell transplantation (ASCT) is an effective therapy for eligible patients with newly diagnosed systemic AL amyloidosis. Dose attenuated melphalan is used in patients with older age, renal dysfun
Autor:
Maurizio Zangari, Antje Hoering, Jeffery R. Sawyer, Pingping Qu, Bart Barlogie, Joshua Epstein, Christoph Heuck, Erming Tian, Frits van Rhee, Gareth J. Morgan
Publikováno v:
Blood. 126:2982-2982
Introduction In multiple myeloma (MM), deletion of chromosome 17 p13 (del17p) is a poor prognostic feature. The percentage of cells carrying an abnormality has been reported to be important with thresholds of 20% being taken generally but thresholds
Autor:
Nelly Nancy Safaian, Ingmar Bruns, Guido Kobbe, Christian Saure, Thomas Schroeder, Roland Fenk, Akos Czibere, Rainer Haas, Fabian Zohren
Publikováno v:
Blood. 114:2057-2057
Abstract 2057 Poster Board II-34 Introduction: Patients with acute myeloid leukemia (AML) and activating mutations in the Fms-like tyrosine-3 (FLT3) gene have an abysmal prognosis. Together with other groups we have recently demonstrated the clinical
Autor:
Ursula Haak, Rita Pasold, Sabine Hahnfels, Thomas-Hein Ittel, Christian Klinkenstein, Sabine Neser, Andreas Neubauer, Franz-Adolph Hoffmann, Ullrich von Gruenhagen, Ullrich Mey, Klaus Dachselt, Dorothee Bleyl, Mathias Freund, Ralph Naumann, Klaus Hieke, Heiner Wolf, Erika Kettner, Thomas Fietz, Volker Lakner, Helga Schwenke, Gottfried Doelken, Detlev Haehling, Henning Eschenburg, Klaus Hoeffken, Michael Assmann, Dietger Niederwieser, Michael Herold, Astrid Franke, Norbert Grobe, Robert Rohrberg, Michael R. Clemens, H.-H. Wolf, Peter Richter
Publikováno v:
Blood. 104:87-87
Background: Clinical superiority of R-MCP (rituximab, mitoxantrone, chlorambucil, prednisolone) vs. MCP alone in patients with advanced stage indolent Non-Hodgkin’s-Lymphoma was demonstrated in a prospective, randomized, controlled, multicenter cli